Specialty Pharma Journal Specialty, Precision & Technology
CRANBURY, N.J., Oct. 5, 2015 /PRNewswire/ — Oncobiologics, Inc. (“Oncobiologics”) announced that its bevacizumab (Avastin®) biosimilar candidate, ONS-1045, met the primary and secondary endpoints in a Phase 1 clinical trial. A 3-arm single-dose pharmacokinetic (PK) study was performed in 135 healthy male volunteers to compare ONS-1045 to both the U.S.- and EU-sourced Avastin® …
Tag Archives: Oncobiologics
October, 2015
July, 2015
-
31 July
Oncobiologics Secures $31 Million to Advance Development of Biosimilars Platform and Pipeline
CRANBURY, N.J., July 27, 2015 /PRNewswire/ — Oncobiologics, Inc., announced the closing of a $31 million financing. Proceeds will be used to support continued development and expansion of the company’s proprietary BioSymphony™ biosimilar platform and advancement of its preclinical and clinical programs. The investment round was led by new investor, Perceptive …
June, 2015
-
12 June
Starting Up in the Biosimilars Market: Oncobiologics’ CEO, Pankaj Mohan, on the Company’s Path to Success
In the race to bring biosimilar products to the market, many industry experts predict that pharma giants will be the winners. However, some emerging biotech companies, such as Oncobiologics, have dared to enter the sector among the established players. How will they survive? At the “Biosimilars 20/20” conference in Philadelphia, …
April, 2015
-
15 April
Oncobiologics’ Biosimilar Candidate of Avastin Completes Clinical Dosing in Pivotal Pharmacokinetic Study
Today, privately-held Oncobiologics, Inc. provided an update on its study evaluating its biosimilar candidate of Avastin (bevacizumab). The biosimilars drugmaker announced that clinical development for its ONS-1045, a biosimilar candidate of Avastin, is underway with dosing completed in its pivotal pharmacokinetic study. The study is currently being conducted in Leiden, …